An Observational, Non-Interventional, Multicentre Study of Immune Thrombocytopenia: The Africa Middle East and Asian Immune Thrombocytopenia Registry

Immune thrombocytopenia (ITP) is a rare bleeding disease caused by autoimmune deregulation, the trigger of which is not completely understood. Lack of platelets, which are crucial for blood clotting, can lead to a higher bleeding risk. A database of children and adults with ITP can help in developing treatment strategies to improve the management of the disease. Therefore, we conducted a multicenter, observational, non-interventional study to collect data from patients with ITP in The Africa, Middle East, and Asian (AMEA) region, and to establish a Web-based database of children and adults with ITP from the AMEA region, which will help in standardizing treatment practices. We included children and adults of any gender with a diagnosis of ITP (platelet count: Of 300 enrolled patients, 250 were analyzed. The mean age of patients was 28.29 (±17.34) years, with 165 Adults and 85 Children. The majority of the patients were females (60.4%). The mean duration of diagnosis was 2.39 (±4.09) years per the available data of 185 patients. Bleeding events were predominant at baseline than at follow-up visits. Most patients were on one or more treatments at the baseline visit (70.8%). Prednisolone was the most commonly used treatment agent (23.2%). The most common co-morbid conditions were hypertension (7.2%) and type 2 diabetes mellitus (7.2%). The percentage of secondary causes of ITP is shown in Table 1. Finally, our study was successful in collecting relevant data and establishing a Web-based database of patients with ITP. This is the first ITP registry database of the African Middle East and Asian region which provided a comprehensive picture of the baseline characteristics, secondary causes, and ITP therapy. This registry will provide a framework towards the design of future protocols aiming at improving outcomes in patients with ITP. Disclosures Alsayegh: Amgen: Research Funding; Sanofi: Research Funding.